Registry of AngioJet Use in the Peripheral Vascular System
NCT ID: NCT01086215
Last Updated: 2014-11-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2010-01-31
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A patient's treatment is determined by the treating physician based on the clinical situation and local practices. In contrast to a randomized, controlled trial, there are no pre-defined experimental interventions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Limb Ischemia
Patients presenting with limb ischemia for treatment
No interventions assigned to this group
Deep Vein Thrombosis
Patients presenting with deep vein thrombosis for treatment
No interventions assigned to this group
Hemodialysis Access
Patients presenting with thrombosed hemodialysis access for treatment
No interventions assigned to this group
Other Thrombotic Conditions
Patients presenting with a thrombotic condition other than limb ischemia, deep vein thrombosis or thrombosed hemodialysis access for treatment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has provided appropriate consent/authorization per the site's institutional policy and procedure.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boston Scientific Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lawrence Blitz, MD
Role: PRINCIPAL_INVESTIGATOR
Chilton Memorial Hospital
Robert Lookstein, MD
Role: STUDY_DIRECTOR
Icahn School of Medicine at Mount Sinai
Ali Amin, MD
Role: PRINCIPAL_INVESTIGATOR
The Reading Hospital & Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Phoenix Heart, PLLC
Glendale, Arizona, United States
John C. Lincoln Deer Valley Hospital
Phoenix, Arizona, United States
Good Samaritan Hospital
Los Angeles, California, United States
Christiana Care Health System
Newark, Delaware, United States
University of Florida- College of Medicine
Jacksonville, Florida, United States
First Coast Cardiovascular Institute
Jacksonville, Florida, United States
Sacred Heart Hospital
Pensacola, Florida, United States
Chris Recknor PC
Gainesville, Georgia, United States
Indiana University Health Arnett
Lafayette, Indiana, United States
Iowa Health
Des Moines, Iowa, United States
Cardiovascular Consultants
Bossier City, Louisiana, United States
Terrebonne General Medical Center
Houma, Louisiana, United States
Regional Medical Center of Acadiana
Lafayette, Louisiana, United States
Chilton Memorial Hospital
Pompton Plains, New Jersey, United States
Mount Sinai School of Medicine
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Forsyth Medical Center
Winston-Salem, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
Grant Medical Center
Columbus, Ohio, United States
Good Samaritan Hospital
Dayton, Ohio, United States
The University of Toledo Medical Center
Toledo, Ohio, United States
St Luke's Hospital & Health Network
Bethlehem, Pennsylvania, United States
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States
The Reading Hospital & Medical Center
Reading, Pennsylvania, United States
The Miriam Hospital
Providence, Rhode Island, United States
University of South Carolina
Charleston, South Carolina, United States
North Central Heart Institute
Sioux Falls, South Dakota, United States
Holston Valley Medical Center
Kingsport, Tennessee, United States
University of Tennessee - Knoxville
Knoxville, Tennessee, United States
Winchester Medical Center
Winchester, Virginia, United States
Charleston Area Medical Center
Charleston, West Virginia, United States
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, United States
Winnipeg Regional Health Authority
Winnipeg, Manitoba, Canada
Städtisches Klinikum Karlsruhe gGmbH
Karlsruhe, , Germany
University of Naples
Naples, , Italy
National Institute of CV Diseases
Bratislava, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Garcia MJ, Lookstein R, Malhotra R, Amin A, Blitz LR, Leung DA, Simoni EJ, Soukas PA. Endovascular Management of Deep Vein Thrombosis with Rheolytic Thrombectomy: Final Report of the Prospective Multicenter PEARL (Peripheral Use of AngioJet Rheolytic Thrombectomy with a Variety of Catheter Lengths) Registry. J Vasc Interv Radiol. 2015 Jun;26(6):777-85; quiz 786. doi: 10.1016/j.jvir.2015.01.036. Epub 2015 Mar 29.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PEARLII
Identifier Type: -
Identifier Source: org_study_id